- Home
- INKT vs ENLV Comparison
INKT vs ENLV Comparison
Compare INKT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ENLV |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 26.6M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | INKT | ENLV |
|---|---|---|
| Price | $11.82 | $0.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $7.00 |
| AVG Volume (30 Days) | 20.6K | ★ 1.1M |
| Earning Date | 11-14-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $0.74 |
| 52 Week High | $76.00 | $2.10 |
Technical Indicators
Market Signals| Indicator | INKT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 31.59 |
| Support Level | $11.33 | $0.80 |
| Resistance Level | $12.31 | $0.88 |
| Average True Range (ATR) | 0.73 | 0.08 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 46.54 | 6.04 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.